PTC Inc is a leading technology company that specializes in providing software solutions for product design, development, and lifecycle management
It focuses on helping businesses in various industries innovate and improve their product performance through advanced technologies such as augmented reality, Internet of Things (IoT), and computer-aided design (CAD). PTC's platform enhances collaboration and efficiency in engineering and manufacturing processes by enabling organizations to connect their physical and digital worlds, ultimately driving better decision-making and faster time-to-market for products.
Let’s dig into the relative performance of Veeva Systems (NYSEVEEV) and its peers as we unravel the now-completed Q3 vertical software earnings season.
PTC trades at $199 per share and has stayed right on track with the overall market, gaining 15.2% over the last six months. At the same time, the S&P 500 has returned 10.6%.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how design software stocks fared in Q3, starting with Autodesk (NASDAQADSK).
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the design software industry, including Procore (NYSEPCOR) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the design software industry, including Cadence (NASDAQCDNS) and its peers.
Engineering and design software provider PTC (NASDAQPTC) met Wall Street’s revenue expectations in Q3 CY2024, with sales up 14.6% year on year to $626.5 million. On the other hand, next quarter’s revenue guidance of $555 million was less impressive, coming in 8.8% below analysts’ estimates. Its GAAP profit of $1.04 per share was 4.6% above analysts’ consensus estimates.
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans to submit for FDA approval in late 2025, addressing a critical patient demographic.
